(2S,5R,6S,9S,12S,13S,16R)-2-ethyl-12-[(3R,5S,6S)-6-methoxy-3,5-dimethyl-7-phenylheptyl]-1,6,13-trimethyl-3,7,10,14,19-pentaoxo-9-(propan-2-yl)-1,4,8,11,15-pentaazacyclononadecane-5,16-dicarboxylic acid

• ChemBase编号: 4287
• 分子式: C40H63N5O10
• 平均质量: 773.95572
• 单一同位素质量: 773.45749324
• SMILES: CC[C@H]1N(C)C(=O)CC[C@H](NC(=O)[C@@H](C)[C@H](CC[C@@H](C)C[C@H](C)[C@H](Cc2ccccc2)OC)NC(=O)[C@@H](NC(=O)[C@@H](C)[C@H](NC1=O)C(=O)O)C(C)C)C(=O)O
• Canonical SMILES: CO[C@H]([C@H](C[C@@H](CC[C@@H]1NC(=O)[C@@H](NC(=O)[C@@H](C)[C@H](NC(=O)[C@H](N(C(=O)CC[C@H](NC(=O)[C@H]1C)C(=O)O)C)CC)C(=O)O)C(C)C)C)C)Cc1ccccc1
• InChI: InChI=1S/C40H63N5O10/c1-10-30-37(49)44-34(40(53)54)26(7)36(48)43-33(22(2)3)38(50)41-28(25(6)35(47)42-29(39(51)52)18-19-32(46)45(30)8)17-16-23(4)20-24(5)31(55-9)21-27-14-12-11-13-15-27/h11-15,22-26,28-31,33-34H,10,16-21H2,1-9H3,(H,41,50)(H,42,47)(H,43,48)(H,44,49)(H,51,52)(H,53,54)/t23-,24+,25+,26+,28+,29-,30+,31+,33+,34-/m1/s1
• InChIKey: MESJISIEDVKBAM-NSKZDGTMSA-N

名称和登记号

名称

• IUPAC标准名: (2S,5R,6S,9S,12S,13S,16R)-2-ethyl-12-[(3R,5S,6S)-6-methoxy-3,5-dimethyl-7-phenylheptyl]-1,6,13-trimethyl-3,7,10,14,19-pentaoxo-9-(propan-2-yl)-1,4,8,11,15-pentaazacyclononadecane-5,16-dicarboxylic acid
• IUPAC传统名: nodularin-V
• 别名: nodularin-V; Motuporin

登记号

• PubChem SID: 46508386; 160967719
• PubChem CID: 46937018

理论计算性质

JChem

• Acid pKa: 3.4556756
• 质子受体: 10
• 质子供体: 6
• LogD (pH = 5.5): -0.12233396
• LogD (pH = 7.4): -3.1996908
• Log P: 3.3590703
• 摩尔折射率: 203.1683 cm^3
• 极化性: 80.01552 Å^3
• 极化表面积: 220.54 Å^2
• 可自由旋转的化学键: 13
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: 2.07
• LOG S: -5.0
• 溶解度: 7.70e-03 g/l

详细说明

DrugBank - DB04738

• Drug Groups: experimental
• Affected Organisms: Humans and other mammals